This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
SAMPLE
Millennium Pharmaceuticals, Inc. – Product Pipeline Review – 2013 GMDHC03730CDB / Published MAY 2013
Table of Contents ............................................................................................................................................................................... 2
List of Tables ................................................................................................................................................................................. 6
List of Figures ................................................................................................................................................................................ 7
Millennium Pharmaceuticals, Inc. Snapshot ....................................................................................................................................... 8
Millennium Pharmaceuticals, Inc. Overview .................................................................................................................................. 8
Key Information ............................................................................................................................................................................. 8
Millennium Pharmaceuticals, Inc. – Research and Development Overview ....................................................................................... 9
Key Therapeutic Areas .................................................................................................................................................................. 9
Millennium Pharmaceuticals, Inc. – Pipeline Review ........................................................................................................................ 13
Pipeline Products by Stage of Development ............................................................................................................................... 13
Millennium Pharmaceuticals, Inc. – Pipeline Products Glance ......................................................................................................... 16
Millennium Pharmaceuticals, Inc. – Late Stage Pipeline ............................................................................................................. 16
Phase III Products/Combination Treatment Modalities ........................................................................................................... 18
Millennium Pharmaceuticals, Inc. Clinical Stage Pipeline Products ............................................................................................. 19
Phase II Products/Combination Treatment Modalities ............................................................................................................ 19
Phase I Products/Combination Treatment Modalities ............................................................................................................. 20
Millennium Pharmaceuticals, Inc. – Early Stage Pipeline Products ............................................................................................. 21
Millennium Pharmaceuticals, Inc. – Drug Profiles ............................................................................................................................ 22
Mechanism of Action ............................................................................................................................................................... 22
Mechanism of Action ............................................................................................................................................................... 23
Mechanism of Action ............................................................................................................................................................... 24
Mechanism of Action ............................................................................................................................................................... 28
Mechanism of Action ............................................................................................................................................................... 29
Mechanism of Action ............................................................................................................................................................... 32
Mechanism of Action ............................................................................................................................................................... 34
Mechanism of Action ............................................................................................................................................................... 35
Mechanism of Action ............................................................................................................................................................... 36
Mechanism of Action ............................................................................................................................................................... 37
Mechanism of Action ............................................................................................................................................................... 39
Mechanism of Action ............................................................................................................................................................... 40
Mechanism of Action ............................................................................................................................................................... 41
Mechanism of Action ............................................................................................................................................................... 43
Mechanism of Action ............................................................................................................................................................... 45
Mechanism of Action ............................................................................................................................................................... 47
Millennium Pharmaceuticals, Inc. – Pipeline Analysis ...................................................................................................................... 49
Millennium Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class .............................................................................. 49
Millennium Pharmaceuticals, Inc. – Pipeline Products by Route of Administration...................................................................... 50
Millennium Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action ......................................................................... 51
Millennium Pharmaceuticals, Inc. – Recent Pipeline Updates ......................................................................................................... 53
Millennium Pharmaceuticals, Inc. - Dormant Projects ...................................................................................................................... 74
Millennium Pharmaceuticals, Inc. - Discontinued Pipeline Products ................................................................................................ 75
Millennium Pharmaceuticals, Inc. – Locations And Subsidiaries ...................................................................................................... 77
Head Office.................................................................................................................................................................................. 77
May 23, 2013: Takeda Initiates TOURMALINE-MM2 Pivotal Phase III Trial Of MLN9708 In Patients With Newly Diagnosed Multiple Myeloma .................................................................................................................................................................... 78
Apr 07, 2013: Millennium Pharma Presents Data From Meta-Analysis Of Velcade Phase III Trial At 14th International Myeloma Workshop ................................................................................................................................................................ 78
Dec 09, 2010: Millennium Reports Phase III Results Of VELCADE Combination Therapy In Multiple Myeloma .................... 80
Dec 09, 2010: Millennium Reports Positive Results From Phase III Trial With VELCADE Based Induction Regimens In Multiple Myeloma .................................................................................................................................................................... 81
Dec 07, 2010: Millennium Reports Phase III Study Final Positive Results Of VELCADE In Combination With Rituximab In Follicular Lymphoma ............................................................................................................................................................... 82
Dec 07, 2010: Millennium Reports Phase III Trial Results Of VELCADE In Multiple Myeloma ............................................... 83
Dec 06, 2010: Millennium Reports Encouraging Phase I Results Of MLN4924 In Acute Myeloid Leukemia .......................... 84
Nov 30, 2010: Intellikine And MMRC Initiate Phase I Trial Of Multiple Myeloma Drug ........................................................... 84
Nov 10, 2010: Velcade Induction And Maintenance Data TO Be Featured In Oral Presentations At American Society Of Hematology Annual Meeting ................................................................................................................................................... 85
Nov 04, 2010: Millennium And Takeda Announce Advancement Of Prostate Cancer Program ............................................. 86
Sep 02, 2010: Millennium Announces Publication Of MLN4924 Preclinical Activity In Lymphoma In Blood ........................... 86
Jul 29, 2010: Millennium Reports Data From Pinnacle Trial Of Velcade In Patients With Relapsed/Refractory Mantle Cell Lymphoma .............................................................................................................................................................................. 87
Jun 07, 2010: Millennium Presents New Clinical Data On MLN9708 For Treatment Of Solid Tumors At ASCO 2010 Meeting ................................................................................................................................................................................................ 88
Jun 07, 2010: Millennium Presents New Clinical Data On TAK-700 For Treatment Of Solid Tumors At ASCO 2010 Meeting ................................................................................................................................................................................................ 88
Jun 07, 2010: Millennium Presents Phase I Clinical Data Of TAK-701 For Treatment Of Solid Tumors At ASCO 2010 Meeting ................................................................................................................................................................................... 89
Jun 07, 2010: Millennium Presents Phase I Data On MLN8237 For Treatment Of Solid Tumors At ASCO 2010 Meeting ..... 89
SAMPLE
Millennium Pharmaceuticals, Inc. – Product Pipeline Review
Millennium Pharmaceuticals, Inc. – Product Pipeline Review – 2013 GMDHC03730CDB / Published MAY 2013
Jun 04, 2010: Millennium Presents Velcade Data On Relapsed Or Refractory Amyloidosis At American Society of Clinical Oncology Annual Meeting ....................................................................................................................................................... 90
May 10, 2010: Takeda To Co-promote VELCADE For Injection In Japan .............................................................................. 91
Mar 09, 2010: Millennium Announces First Clinical Data For TAK-700 Prostate Molecule At ASCO GU ............................... 92
Jan 15, 2010: Takeda Oncology Announces Publication Of Millenium's Enzyme Inhibitor MLN4924 In The Molecular Cell Journal .................................................................................................................................................................................... 92
Jan 05, 2010: Intellikine Initiates Phase I Clinical Trial Of INK128 For The Prevention Of Cancer ......................................... 93
Jan 05, 2010: Takeda Receives Additional Approval Of Velcader (Bortezomib) For The Treatment Of Multiple Myeloma .... 94
Jan 04, 2010: The Addition of VELCADE (Bortezomib) for Injection to Novel Combination Delivers Promising Results in Patients With Non-Hodgkin‘s Lymphoma ................................................................................................................................ 94
Jan 04, 2010: FDA Approves Addition Of Sustained Overall Survival Benefit To Label For Velcade (Bortezomib) Injection For Patients With Previously Untreated Multiple Myeloma ............................................................................................................ 95
Infinity Pharma Amends Licensing Agreement With Millennium Pharma .............................................................................. 105
Millennium Enters Into Licensing Agreement With Sunesis Pharma ..................................................................................... 107
Seattle Genetics Extends Licensing Agreement With Millennium ......................................................................................... 109
Seattle Genetics Enters Into Licensing Agreement With Millennium Pharma ....................................................................... 110
Trigen Enters Into Licensing Agreement With Millennium Pharma ....................................................................................... 111
Secondary Research ................................................................................................................................................................. 116
Primary Research ...................................................................................................................................................................... 116
Millennium Pharmaceuticals, Inc. – Pipeline by Indication, 2013 ..................................................................................................... 10
Millennium Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2013 ................................................................................. 13
Millennium Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2013 .................................................................................. 14
Millennium Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2013 ............................................................... 15
Millennium Pharmaceuticals, Inc. – Filed, 2013 ............................................................................................................................... 16
Millennium Pharmaceuticals, Inc. – Filing Rejected/Withdrawn, 2013 .............................................................................................. 17
Millennium Pharmaceuticals, Inc. – Phase III, 2013 ......................................................................................................................... 18
Millennium Pharmaceuticals, Inc. – Phase II, 2013 .......................................................................................................................... 19
Millennium Pharmaceuticals, Inc. – Phase I, 2013 ........................................................................................................................... 20
Millennium Pharmaceuticals, Inc. – Pre-Clinical, 2013 ..................................................................................................................... 21
Millennium Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2013........................................................................................ 49
Millennium Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2013 ............................................................................... 50
Millennium Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action, 2013 .................................................................... 52
Millennium Pharmaceuticals, Inc. – Recent Pipeline Updates, 2013 ................................................................................................ 53
Millennium Pharmaceuticals, Inc. - Dormant Developmental Projects,2013..................................................................................... 74
Millennium Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2013 ...................................................................................... 75
Seattle Genetics And Millennium Pharma Enter Into Co-Development Agreement With Ventana Medical Systems ....................... 98
Presage Biosciences Enters Into Co-Development Agreement With Millennium Pharma For Cancer Drugs .................................. 99
Millenium: The Takeda Oncology Enters Into Research Collaboration With Therasis .................................................................... 100
Seattle Genetics Enters Into Co-Development Agreement With Millennium .................................................................................. 102
Millennium Enters Into Co-Development Agreement With Harvard Medical School ....................................................................... 104
Infinity Pharma Amends Licensing Agreement With Millennium Pharma ....................................................................................... 105
Millennium Enters Into Licensing Agreement With Sunesis Pharma .............................................................................................. 107
Seattle Genetics Extends Licensing Agreement With Millennium .................................................................................................. 109
Seattle Genetics Enters Into Licensing Agreement With Millennium Pharma................................................................................. 110
Trigen Enters Into Licensing Agreement With Millennium Pharma ................................................................................................. 111
Millennium Pharma Completes Public Offering Of 2.25% Senior Notes For US$250 Million ......................................................... 112
Takeda Acquires Millennium Pharma For US$8.8 Billion ............................................................................................................... 114
SAMPLE
Millennium Pharmaceuticals, Inc. – Product Pipeline Review
Millennium Pharmaceuticals, Inc. – Product Pipeline Review – 2013 GMDHC03730CDB / Published MAY 2013
Millennium Pharmaceuticals, Inc. – Pipeline by Indication, 2013 .................................................................................................... 10
Millennium Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2013 ................................................................................ 13
Millennium Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2013 .................................................................................. 14
Millennium Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2013 ............................................................... 15
Millennium Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2013 .............................................................................. 50
Millennium Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2013 .................................................................... 51
SAMPLE
Millennium Pharmaceuticals, Inc. – Product Pipeline
Review
Millennium Pharmaceuticals, Inc. – Product Pipeline Review – 2013 GMDHC03730CDB / Published MAY 2013